Indu Barwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Indu Barwal has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Subhash Chandra Yadav
All India Institute of Medical Sciences 2 Electron Microscope Facility, Department of Anatomy 110029 New Delhi
3 shared publications Subhash C. Yadav
2 shared publications- Suneel Kateriya
Laboratory of Optobiotechnology, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India
2 shared publications Abdul Majeed
Department of Orthopaedics, All India Institute of Medical Sciences, New Delhi 110029, India
1 shared publication- Abhishek Gupta
School of Basic Sciences, Indian Institute of Technology Mandi, Himachal Pradesh, India
1 shared publication Adarsh W. Barwad
Department of Pathology, All India Institute of Medical Sciences, New Delhi 110029, India
1 shared publication
Latest Publications
- 1 June 2019
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 25 (6) , 1376-1382
Processing Techniques for Scanning Electron Microscopy Imaging of Giant Cells from Giant Cell Tumors of Bone
Giant cell tumor (GCT) of bone is a common benign lesion that causes significant morbidity due to the failure of modern medical and surgical treatment. Surface ultra-structures of giant cells (GCs) may help in distinguishing aggressive tumors from indolent GC lesions. This study aimed to standardize scanning electron microscopic (SEM) imaging of GC from GCT of bone. Fresh GCT collected in Dulbecco's Modified Eagle Medium was washed to remove blood, homogenized, or treated with collagenase to isolate the GCs. Mechanically homogenized and collagenase-digested GCs were imaged on SEM after commonly used drying methodologies such as air-drying, tetramethylsilane (TMS)-drying, freeze-drying, and critical point-drying (CPD) for the optimization of sample processing. The collagenase-treated samples yielded a greater number of isolated GC and showed better surface morphology in comparison to mechanical homogenization. Air-drying was associated with marked cell shrinkage, and freeze-dried samples showed severe cell damage. TMS methodology partially preserved the cell contour and surface structures, although the cell shape was distorted. GC images with optimum surface morphology including membrane folding and microvesicular structures on the surface were observed only in collagenase-treated and critical point-dried samples. Collagenase digestion and critical point/TMS-drying should be performed for optimal SEM imaging of individual GCs.
- 1 June 2019
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 25 (6) , 1376-1382
Processing Techniques for Scanning Electron Microscopy Imaging of Giant Cells from Giant Cell Tumors of Bone
Giant cell tumor (GCT) of bone is a common benign lesion that causes significant morbidity due to the failure of modern medical and surgical treatment. Surface ultra-structures of giant cells (GCs) may help in distinguishing aggressive tumors from indolent GC lesions. This study aimed to standardize scanning electron microscopic (SEM) imaging of GC from GCT of bone. Fresh GCT collected in Dulbecco's Modified Eagle Medium was washed to remove blood, homogenized, or treated with collagenase to isolate the GCs. Mechanically homogenized and collagenase-digested GCs were imaged on SEM after commonly used drying methodologies such as air-drying, tetramethylsilane (TMS)-drying, freeze-drying, and critical point-drying (CPD) for the optimization of sample processing. The collagenase-treated samples yielded a greater number of isolated GC and showed better surface morphology in comparison to mechanical homogenization. Air-drying was associated with marked cell shrinkage, and freeze-dried samples showed severe cell damage. TMS methodology partially preserved the cell contour and surface structures, although the cell shape was distorted. GC images with optimum surface morphology including membrane folding and microvesicular structures on the surface were observed only in collagenase-treated and critical point-dried samples. Collagenase digestion and critical point/TMS-drying should be performed for optimal SEM imaging of individual GCs.
- 25 April 2019
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 25 (6) , 1352-1366
Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Brimonidine, an anti-glaucoma medicine, acts as an adrenergic agonist which decreases the synthesis of aqueous humour and increases the amount of drainage through Schlemm's canal and trabecular meshwork, but shows dose-dependent (0.2% solution thrice daily) toxicity. To reduce the side effects and improve the efficacy, brimonidine was nanoencapsulated on ultra-small-sized chitosan nanoparticles (nanobrimonidine) (28 ± 4 nm) with 39% encapsulation efficiency, monodispersity, freeze–thawing capability, storage stability, and 2% drug loading capacity. This nanocomplex showed burst, half, and complete release at 0.5, 45, and 100 h, respectively. Nanobrimonidine did not show anyin vitrotoxicity and was taken up by caveolae-mediated endocytosis. The nanobrimonidine-treated trabeculectomy tissue of glaucoma patients showed better dilation of the trabecular meshwork under the electron microscope. This is direct evidence for better bioavailability of nanobrimonidine after topical administration. Thus, the developed nanobrimonidine has the potential to improve the efficacy, reduce dosage and frequency, and improve delivery to the anterior chamber of the eye.
- 25 April 2019
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 25 (6) , 1352-1366
Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Brimonidine, an anti-glaucoma medicine, acts as an adrenergic agonist which decreases the synthesis of aqueous humour and increases the amount of drainage through Schlemm's canal and trabecular meshwork, but shows dose-dependent (0.2% solution thrice daily) toxicity. To reduce the side effects and improve the efficacy, brimonidine was nanoencapsulated on ultra-small-sized chitosan nanoparticles (nanobrimonidine) (28 ± 4 nm) with 39% encapsulation efficiency, monodispersity, freeze–thawing capability, storage stability, and 2% drug loading capacity. This nanocomplex showed burst, half, and complete release at 0.5, 45, and 100 h, respectively. Nanobrimonidine did not show anyin vitrotoxicity and was taken up by caveolae-mediated endocytosis. The nanobrimonidine-treated trabeculectomy tissue of glaucoma patients showed better dilation of the trabecular meshwork under the electron microscope. This is direct evidence for better bioavailability of nanobrimonidine after topical administration. Thus, the developed nanobrimonidine has the potential to improve the efficacy, reduce dosage and frequency, and improve delivery to the anterior chamber of the eye.
- Open Access
- 22 November 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 37096
Targeted delivery system for cancer cells consist of multiple ligands conjugated genetically modified CCMV capsid on doxorubicin GNPs complex
Targeted nano-delivery vehicles were developed from genetically modified Cowpea chlorotic mottle virus (CCMV) capsid by ligands bioconjugation for efficient drug delivery in cancer cells. RNA binding (N 1-25aa) and β-hexamer forming (N 27-41aa) domain of capsid was selectively deleted by genetic engineering to achieve the efficient in vitro assembly without natural cargo. Two variants of capsids were generated by truncating 41 and 26 amino acid from N terminus (NΔ41 and NΔ26) designated as F1 and F2 respectively. These capsid were optimally self-assembled in 1:2 molar ratio (F1:F2) to form a monodisperse nano-scaffold of size 28 nm along with chemically conjugated modalities for visualization (fluorescent dye), targeting (folic acid, FA) and anticancer drug (doxorubicin). The cavity of the nano-scaffold was packed with doxorubicin conjugated gold nanoparticles (10 nm) to enhance the stability, drug loading and sustained release of drug. The chimeric system was stable at pH range of 4–8. This chimeric nano-scaffold system showed highly specific receptor mediated internalization (targeting) and ~300% more cytotoxicity (with respect to FA− delivery system) to folate receptor positive Michigan Cancer Foundation-7 (MCF7) cell lines. The present system may offer a programmable nano-scaffold based platform for developing chemotherapeutics for cancer.
- 22 November 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 37096
Open AccessTargeted delivery system for cancer cells consist of multiple ligands conjugated genetically modified CCMV capsid on doxorubicin GNPs complex
Targeted nano-delivery vehicles were developed from genetically modified Cowpea chlorotic mottle virus (CCMV) capsid by ligands bioconjugation for efficient drug delivery in cancer cells. RNA binding (N 1-25aa) and β-hexamer forming (N 27-41aa) domain of capsid was selectively deleted by genetic engineering to achieve the efficient in vitro assembly without natural cargo. Two variants of capsids were generated by truncating 41 and 26 amino acid from N terminus (NΔ41 and NΔ26) designated as F1 and F2 respectively. These capsid were optimally self-assembled in 1:2 molar ratio (F1:F2) to form a monodisperse nano-scaffold of size 28 nm along with chemically conjugated modalities for visualization (fluorescent dye), targeting (folic acid, FA) and anticancer drug (doxorubicin). The cavity of the nano-scaffold was packed with doxorubicin conjugated gold nanoparticles (10 nm) to enhance the stability, drug loading and sustained release of drug. The chimeric system was stable at pH range of 4–8. This chimeric nano-scaffold system showed highly specific receptor mediated internalization (targeting) and ~300% more cytotoxicity (with respect to FA− delivery system) to folate receptor positive Michigan Cancer Foundation-7 (MCF7) cell lines. The present system may offer a programmable nano-scaffold based platform for developing chemotherapeutics for cancer.
- 1 March 2015
- Published by Elsevier in Food Bioscience
- Vol. 9, 28-35
Methodology to nanoencapsulate hepatoprotective components from Picrorhiza kurroa as food supplement
- 1 March 2015
- Published by Elsevier in Food Bioscience
- Vol. 9, 28-35
Methodology to nanoencapsulate hepatoprotective components from Picrorhiza kurroa as food supplement
- 1 April 2014
- Published by American Scientific Publishers in Journal of Bionanoscience
- Vol. 8 (2) , 137-140
Rebaudioside A Loaded Poly-D,L-Lactide-Nanoparticles as an Anti-Diabetic Nanomedicine
Rebaudioside A is a major constituent (20% w/w) of natural stevioside powder and possess strong insulinotropic (anti-diabetic) activity with an extra glucose molecule than stevioside. In this manuscript, we have reported the nanofabrication of pure rebaudioside A and its effect on size, encapsulation efficiency and in vitro release. These results have been compared with stevioside nanoparticles using same synthesis process to evaluate the effect of extra glycosylation on nanoencapsulation (Colloids and surfaces B: Biointerfaces, 101 (2013) 510–516). Mono-disperse rebaudioside A-PLA nanoparticles of larger size (150–200 nm) than stevioside NPs (110–130 nm) were obtained along with 28.57% molecular loading efficiency (w/w%). However, rebaudioside A-PLA nanoparticle shows similar in vitro burst and sustained release upto 200 h as nano-stevioside. This study reveals that rebaudioside A-PLA nanoparticles can be used as a better antidiabetic nanomedicine than previously reported stevioside PLA nanoparticles.
- 1 April 2014
- Published by American Scientific Publishers in Journal of Bionanoscience
- Vol. 8 (2) , 137-140
Rebaudioside A Loaded Poly-D,L-Lactide-Nanoparticles as an Anti-Diabetic Nanomedicine
Rebaudioside A is a major constituent (20% w/w) of natural stevioside powder and possess strong insulinotropic (anti-diabetic) activity with an extra glucose molecule than stevioside. In this manuscript, we have reported the nanofabrication of pure rebaudioside A and its effect on size, encapsulation efficiency and in vitro release. These results have been compared with stevioside nanoparticles using same synthesis process to evaluate the effect of extra glycosylation on nanoencapsulation (Colloids and surfaces B: Biointerfaces, 101 (2013) 510–516). Mono-disperse rebaudioside A-PLA nanoparticles of larger size (150–200 nm) than stevioside NPs (110–130 nm) were obtained along with 28.57% molecular loading efficiency (w/w%). However, rebaudioside A-PLA nanoparticle shows similar in vitro burst and sustained release upto 200 h as nano-stevioside. This study reveals that rebaudioside A-PLA nanoparticles can be used as a better antidiabetic nanomedicine than previously reported stevioside PLA nanoparticles.
- 1 January 2013
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 101, 510-516
Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine
- 1 January 2013
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 101, 510-516
Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine
- Open Access
- 7 December 2011
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 9 (1) , 56
Cellular oxido-reductive proteins of Chlamydomonas reinhardtii control the biosynthesis of silver nanoparticles
Background: Elucidation of molecular mechanism of silver nanoparticles (SNPs) biosynthesis is important to control its size, shape and monodispersity. The evaluation of molecular mechanism of biosynthesis of SNPs is of prime importance for the commercialization and methodology development for controlling the shape and size (uniform distribution) of SNPs. The unicellular algae Chlamydomonas reinhardtii was exploited as a model system to elucidate the role of cellular proteins in SNPs biosynthesis. Results: The C. reinhardtii cell free extract (in vitro) and in vivo cells mediated synthesis of silver nanoparticles reveals SNPs of size range 5 ± 1 to 15 ± 2 nm and 5 ± 1 to 35 ± 5 nm respectively. In vivo biosynthesized SNPs were localized in the peripheral cytoplasm and at one side of flagella root, the site of pathway of ATP transport and its synthesis related enzymes. This provides an evidence for the involvement of oxidoreductive proteins in biosynthesis and stabilization of SNPs. Alteration in size distribution and decrease of synthesis rate of SNPs in protein-depleted fractions confirmed the involvement of cellular proteins in SNPs biosynthesis. Spectroscopic and SDS-PAGE analysis indicate the association of various proteins on C. reinhardtii mediated in vivo and in vitro biosynthesized SNPs. We have identified various cellular proteins associated with biosynthesized (in vivo and in vitro) SNPs by using MALDI-MS-MS, like ATP synthase, superoxide dismutase, carbonic anhydrase, ferredoxin-NADP+ reductase, histone etc. However, these proteins were not associated on the incubation of pre-synthesized silver nanoparticles in vitro. Conclusion: Present study provides the indication of involvement of molecular machinery and various cellular proteins in the biosynthesis of silver nanoparticles. In this report, the study is mainly focused towards understanding the role of diverse cellular protein in the synthesis and capping of silver nanoparticles using C. reinhardtii as a model system.
- 7 December 2011
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 9 (1) , 56
Open AccessCellular oxido-reductive proteins of Chlamydomonas reinhardtii control the biosynthesis of silver nanoparticles
Background: Elucidation of molecular mechanism of silver nanoparticles (SNPs) biosynthesis is important to control its size, shape and monodispersity. The evaluation of molecular mechanism of biosynthesis of SNPs is of prime importance for the commercialization and methodology development for controlling the shape and size (uniform distribution) of SNPs. The unicellular algae Chlamydomonas reinhardtii was exploited as a model system to elucidate the role of cellular proteins in SNPs biosynthesis. Results: The C. reinhardtii cell free extract (in vitro) and in vivo cells mediated synthesis of silver nanoparticles reveals SNPs of size range 5 ± 1 to 15 ± 2 nm and 5 ± 1 to 35 ± 5 nm respectively. In vivo biosynthesized SNPs were localized in the peripheral cytoplasm and at one side of flagella root, the site of pathway of ATP transport and its synthesis related enzymes. This provides an evidence for the involvement of oxidoreductive proteins in biosynthesis and stabilization of SNPs. Alteration in size distribution and decrease of synthesis rate of SNPs in protein-depleted fractions confirmed the involvement of cellular proteins in SNPs biosynthesis. Spectroscopic and SDS-PAGE analysis indicate the association of various proteins on C. reinhardtii mediated in vivo and in vitro biosynthesized SNPs. We have identified various cellular proteins associated with biosynthesized (in vivo and in vitro) SNPs by using MALDI-MS-MS, like ATP synthase, superoxide dismutase, carbonic anhydrase, ferredoxin-NADP+ reductase, histone etc. However, these proteins were not associated on the incubation of pre-synthesized silver nanoparticles in vitro. Conclusion: Present study provides the indication of involvement of molecular machinery and various cellular proteins in the biosynthesis of silver nanoparticles. In this report, the study is mainly focused towards understanding the role of diverse cellular protein in the synthesis and capping of silver nanoparticles using C. reinhardtii as a model system.